Directly silencing of either MUC1 or NRG1 by siRNA significantly inhibited NSCLC cell growth and tumour formation in vitro and in vivo, implying that they can be used as potential therapeutic targets for NSCLC. This evidence concerns the gene MUC1 and neoplasm.